Inovalon (INOV) Releases Quarterly Earnings Results

Inovalon (NASDAQ:INOV) posted its quarterly earnings results on Tuesday. The technology company reported $0.06 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.07 by ($0.01), Bloomberg Earnings reports. The business had revenue of $114.60 million during the quarter, compared to analyst estimates of $116.83 million. Inovalon had a return on equity of 4.63% and a net margin of 4.07%. The business’s revenue was up 19.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.05 EPS. Inovalon updated its FY18 guidance to $0.31-0.35 EPS.

Shares of Inovalon (NASDAQ:INOV) remained flat at $$12.70 during mid-day trading on Tuesday. The company’s stock had a trading volume of 357,123 shares, compared to its average volume of 491,419. The company has a debt-to-equity ratio of 0.31, a current ratio of 5.62 and a quick ratio of 5.62. The stock has a market cap of $1,850.00 and a price-to-earnings ratio of 105.83. Inovalon has a 1 year low of $10.45 and a 1 year high of $17.80.

In related news, insider Shauna L. Vernal sold 44,270 shares of the business’s stock in a transaction on Tuesday, January 23rd. The shares were sold at an average price of $14.00, for a total transaction of $619,780.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Robert A. Wychulis sold 85,828 shares of the business’s stock in a transaction on Tuesday, December 5th. The stock was sold at an average price of $15.54, for a total transaction of $1,333,767.12. Following the transaction, the president now owns 466,286 shares of the company’s stock, valued at approximately $7,246,084.44. The disclosure for this sale can be found here. Insiders own 48.28% of the company’s stock.

Several equities analysts have commented on the stock. Zacks Investment Research downgraded shares of Inovalon from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. BidaskClub downgraded shares of Inovalon from a “sell” rating to a “strong sell” rating in a research note on Thursday, December 14th. Two investment analysts have rated the stock with a sell rating and five have given a hold rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $13.00.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at

About Inovalon

Inovalon Holdings, Inc (Inovalon) is a technology company. The Company provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models to the healthcare industry. Leveraging large-scale data interconnectivity capabilities, unparalleled proprietary data sets, advanced analytics, data-driven intervention systems, and subject matter expertise, Inovalon enables the assessment and improvement of clinical and quality outcomes and financial performance across the healthcare ecosystem.

Earnings History for Inovalon (NASDAQ:INOV)

Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with's FREE daily email newsletter.

Leave a Reply